Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.
Company takeovers with promises of more cash down the road ticked up this year, a new Evaluate Vantage analysis finds.
US approvals of high-risk medical devices are way down.
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
IPOs in the medical device sector are bigger than in biotech, but performance, at least of the biggest groups, is mixed.
Device deal making is back in a big way, despite the munificence of venture funds.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.